发布求助
文献互助 智能选刊 最新文献

Current Opinion in Immunology最新文献

筛选
英文 中文
Metabolic regulation of the immune cell in psoriasis: mechanisms and interventions 银屑病免疫细胞的代谢调节：机制和干预
IF 6.6 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-07-16 DOI: 10.1016/j.coi.2025.102614
Dan Hong , Hui Xiong , Siyao Lu , Jianchi Ma , Zhenrui Shi
{"title":"Metabolic regulation of the immune cell in psoriasis: mechanisms and interventions","authors":"Dan Hong ,&nbsp;Hui Xiong ,&nbsp;Siyao Lu ,&nbsp;Jianchi Ma ,&nbsp;Zhenrui Shi","doi":"10.1016/j.coi.2025.102614","DOIUrl":"10.1016/j.coi.2025.102614","url":null,"abstract":"<div><div>Psoriasis is increasingly recognized as a metabolically regulated inflammatory skin disease. Aberrant glycolysis, oxidative phosphorylation, lipid metabolism, and amino acid metabolism reshape T cell, dendritic cell, macrophage, and neutrophil responses, driving chronic inflammation. Keratinocyte-derived metabolites further amplify immune dysfunction, establishing a reciprocal metabolic–immune circuit. Targeting immunometabolic checkpoints, including glucose transporter transporters, mammalian target of rapamycin signaling, and amino acid transporters, offers promising strategies to modulate pathogenic immune responses. This review highlights the metabolic reprogramming of key immune subsets in psoriasis and outlines future directions for developing selective metabolic interventions to improve therapeutic outcomes in this disease context.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102614"},"PeriodicalIF":6.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping economic outcomes: how biosimilars enhance access to health systems in Latin America and the Caribbean 绘制经济成果：生物仿制药如何促进拉丁美洲和加勒比卫生系统的可及性
IF 6.6 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-07-10 DOI: 10.1016/j.coi.2025.102606
María Herrán , Juan-Manuel Anaya
{"title":"Mapping economic outcomes: how biosimilars enhance access to health systems in Latin America and the Caribbean","authors":"María Herrán ,&nbsp;Juan-Manuel Anaya","doi":"10.1016/j.coi.2025.102606","DOIUrl":"10.1016/j.coi.2025.102606","url":null,"abstract":"<div><div>Biological therapy has revolutionized the treatment landscape of complex and chronic conditions, including autoimmune diseases and cancer. However, their high costs have significantly limited patient access, particularly in low- and middle-income regions, such as Latin America and the Caribbean (LAC). As cost-effective alternatives, biosimilars have shown the potential to transform this paradigm and improve access to care. This narrative review examines the role of biosimilars in transforming health care across LAC. It highlights their potential to reduce treatment costs, expand access to essential medicines, promote market competition, and ease financial pressures on health systems. The biosimilars industry in LAC is expected to experience accelerated growth, driven by regulatory enhancements, market dynamics, investments, and a greater emphasis on education. Developing the biosimilar industry will improve health care resiliency, economic stability, and patient access throughout LAC.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102606"},"PeriodicalIF":6.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of epigenetics in inflammatory memory 表观遗传学在炎症记忆中的作用。
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-04 DOI: 10.1016/j.coi.2025.102630
Yaqin Yu , Yueqi Qiu , Ming Zhao
{"title":"The role of epigenetics in inflammatory memory","authors":"Yaqin Yu ,&nbsp;Yueqi Qiu ,&nbsp;Ming Zhao","doi":"10.1016/j.coi.2025.102630","DOIUrl":"10.1016/j.coi.2025.102630","url":null,"abstract":"<div><div>Inflammatory memory refers to the ability of an organism to mount a stronger or faster response upon re-exposure to similar inflammatory stimuli. This heightened sensitivity was once thought to be a unique characteristic of immune cells. However, recent studies have challenged this traditional view, revealing that inflammatory memory is a widely prevalent phenomenon that extends beyond immune cells to include nonimmune cells. These studies indicate that the formation and maintenance of inflammatory memory largely depend on the regulation of epigenetics. Epigenetics involves heritable changes in gene expression without altering the DNA sequence, including mechanisms such as DNA methylation and histone modifications. These modifications regulate gene transcription and influence the cellular response to inflammatory stimuli. In this review, we will discuss the epigenetic mechanisms of inflammatory memory in both immune and nonimmune cells, focusing on new mechanistic insights from the past few years, and briefly discuss the unknowns and future strategies.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102630"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can we cure lupus? 我们能治愈狼疮吗？
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-14 DOI: 10.1016/j.coi.2025.102640
Tessa L Clement, Philip L Cohen
{"title":"Can we cure lupus?","authors":"Tessa L Clement,&nbsp;Philip L Cohen","doi":"10.1016/j.coi.2025.102640","DOIUrl":"10.1016/j.coi.2025.102640","url":null,"abstract":"<div><div>A general understanding of the mechanisms leading to the development of systemic lupus has emerged over recent years, yet treatment of the illness remains largely empiric and unsatisfactory. Targeted therapy with monoclonal antibodies directed against B cells and against cytokines has met limited success, as has therapy with mesenchymal and hematopoietic stem cells. In the last few years, treatment of refractory disease with chimeric-antigen reactive T cells directed against B cells (CAR-T cells) has shown unexpected promise in small patient series, with apparent long-term and complete remission of disease. Rapid progress in this area is likely to result in improved T cell and natural killer (NK) cell treatment of patients with more readily accessible and practical methods. In parallel, increased understanding of systemic lupus erythematosus disease mechanisms using systems biology and single-cell approaches is likely to uncover additional pathways to intervene in the pathogenesis of disease, raising hopes that additional options will be available for long-term treatment or cure of the disease or even prevention of disease in susceptible individuals.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102640"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From metabolomics to transfusion-associated immunomodulation 从代谢组学到输血相关免疫调节
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-22 DOI: 10.1016/j.coi.2025.102646
Angelo D’Alessandro , James C Zimring
{"title":"From metabolomics to transfusion-associated immunomodulation","authors":"Angelo D’Alessandro ,&nbsp;James C Zimring","doi":"10.1016/j.coi.2025.102646","DOIUrl":"10.1016/j.coi.2025.102646","url":null,"abstract":"<div><h3>Purpose of review</h3><div>This review summarizes recent advances in metabolomics that have enhanced our understanding of transfusion-related immunomodulation (TRIM), highlighting how biochemical changes in stored blood products — with a focus on packed red blood cells — affect recipient immune responses.</div></div><div><h3>Recent findings</h3><div>Metabolomics has revealed critical biochemical shifts — termed storage lesions — in blood products, notably accumulation of oxidized lipids, extracellular vesicles, and hemolysis-derived molecules, such as free heme and iron. These metabolites influence recipient immunity by triggering both inflammatory and immunosuppressive pathways, mediated through mechanisms involving redox imbalance, inflammasome activation, and modulation of immune cell metabolism. Studies underscore that the immunological outcomes of transfusions are shaped not only by storage duration but also by donor-specific metabolic profiles influenced by genetics, diet, and environmental exposures. Metabolic profiling has identified novel biomarkers, such as hypoxanthine and kynurenine, which correlate with transfusion quality and immunological impact.</div></div><div><h3>Summary</h3><div>Metabolomics has transformed our understanding of TRIM, emphasizing that transfusion is an active biochemical intervention rather than passive fluid replacement. Moving forward, integrating metabolomic insights into transfusion medicine promises personalized strategies — selecting blood units based on metabolic rather than chronological age and donor characteristics — thus improving safety and clinical outcomes in transfusion recipients.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102646"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144886800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential immune consequences of cold-stored platelet transfusion 冷藏血小板输注的潜在免疫后果
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-19 DOI: 10.1016/j.coi.2025.102645
Kimberly A Thomas , Rachael P Jackman
{"title":"Potential immune consequences of cold-stored platelet transfusion","authors":"Kimberly A Thomas ,&nbsp;Rachael P Jackman","doi":"10.1016/j.coi.2025.102645","DOIUrl":"10.1016/j.coi.2025.102645","url":null,"abstract":"<div><div>The rising interest in using cold-stored platelets (CSP) for improving outcomes in patients with active bleeding has led to multiple clinical trials with the goal of determining the <em>in vivo</em> hemostatic efficacy of CSP compared to standard-of-care room temperature–stored platelets. These trials are concentrated predominantly on safety and hemostatic efficacy measurements in response to therapeutic transfusion with CSP, with safety focused on the usual immune-mediated adverse reactions associated with transfusion, such as allergic and alloimmune reactions. However, given the established relationship between thrombosis and inflammation/immune activation as seen in atherosclerosis, autoimmune disease, and infection (to include the recent COVID-19 pandemic), the goal of this review is to highlight additional mechanisms by which CSP may potentiate or dampen immune activity in the context of therapeutic CSP transfusion in actively bleeding patients, thus highlighting areas of future research.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102645"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144866545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights and perspectives into the discovery of complement-related biomarkers in cancer 在癌症中发现补体相关生物标志物的见解和观点
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.coi.2025.102633
Daniel Ajona , Janire Debersaques , Ruben Pio
{"title":"Insights and perspectives into the discovery of complement-related biomarkers in cancer","authors":"Daniel Ajona ,&nbsp;Janire Debersaques ,&nbsp;Ruben Pio","doi":"10.1016/j.coi.2025.102633","DOIUrl":"10.1016/j.coi.2025.102633","url":null,"abstract":"<div><div>The complement system, a central component of innate immunity, is implicated in tumor biology, influencing processes such as tumor progression, immune evasion, and response to therapy. Numerous studies have identified alterations in complement effectors, activation products, regulatory proteins, and receptors in patients with cancer. These findings underscore the potential of complement-derived biomarkers for enhancing cancer diagnosis, prognosis, or treatment guidance across various oncology settings. However, despite substantial progress in discovery and early validation, no complement-related biomarker has yet been integrated into routine oncology practice. Key challenges in the field include the biological complexity of the complement system, variability in testing methods, and the lack of standardized protocols for sample collection, processing, and analysis. Addressing these issues is essential to ensure reliable and reproducible measurements. Moreover, the clinical utility of these biomarkers depends on their validation in real-world settings, as well as their integration with other molecular markers, advanced imaging, radiomics, and artificial intelligence tools. Advancing the development of harmonized assays and reference materials will be critical for the translation of complement biomarkers into clinical use in cancer. This review summarizes current knowledge on complement-related biomarkers in oncology, highlights technical and conceptual challenges, and discusses future directions to fully harness the potential of the complement system in cancer care.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102633"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can we cure antiphospholipid syndrome? 我们能治愈抗磷脂综合征吗？
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.coi.2025.102610
Pier Luigi Meroni , Enrico Capobianco , Francesco Tedesco
{"title":"Can we cure antiphospholipid syndrome?","authors":"Pier Luigi Meroni ,&nbsp;Enrico Capobianco ,&nbsp;Francesco Tedesco","doi":"10.1016/j.coi.2025.102610","DOIUrl":"10.1016/j.coi.2025.102610","url":null,"abstract":"<div><div>Antiphospholipid antibody syndrome (APS) is a vasculopathy with recurrent thrombosis and/or miscarriages mediated by autoantibodies against PL-binding proteins (aPL), mainly beta2glycoprotein I (β2GPI). While clotting is the key in vascular APS, thrombosis is not critical for placenta pathology. Despite that, anticoagulant/antiplatelet drugs are the leading treatments, but this is not a ‘one-size-fits-all’ therapy, and recurrences are reported. Additional therapies (e.g. antimalarials, statins) and a better characterization of the individual risk profile may improve the outcome. Nevertheless, we are still unable to ‘cure’ APS. The ideal target would be aPL suppression. However, immunosuppression or even B-cell therapies are not effective. Targeting CD38 on antibody-producing cells or anti-CD19 CAR-T cell therapy are promising alternatives, as well as the chimeric autoantigen receptor T cell therapy, due to the identification of β2GPI as an APS autoantigen. Further therapies aimed at improving clot lysis or affecting β2GPI/anti-β2GPI tissue complex formation are appealing preclinical perspectives.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102610"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B cell–targeted therapies in autoimmune skin disease: current advances and challenges 自身免疫性皮肤病的B细胞靶向治疗：目前的进展和挑战
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-14 DOI: 10.1016/j.coi.2025.102643
Zhi Hu , Ming Zhao
{"title":"B cell–targeted therapies in autoimmune skin disease: current advances and challenges","authors":"Zhi Hu ,&nbsp;Ming Zhao","doi":"10.1016/j.coi.2025.102643","DOIUrl":"10.1016/j.coi.2025.102643","url":null,"abstract":"<div><div>Autoimmune skin diseases (AISDs) constitute a group of skin disorders driven by B cell–mediated autoimmunity or dysregulation of other immune cell populations. AISD can be further divided into systemic autoimmune disease with skin involvement, such as systemic lupus erythematosus (SLE), and skin-specific autoimmune disease, such as pemphigus vulgaris (PV). Due to autoreactivity, B cells and autoantibody production play a pivotal role in B cell–driven AISDs. B cell–targeted therapies have become a major focus in research and clinical practice. Recent strategies targeting various B cell have shown promise, whereas several challenges remain in the clinical application. Patient heterogeneity results in variable therapeutic outcomes. Additionally, prolonged B cell suppression increases the risk of infections. Here, this review outlines the B cell–targeted therapeutic approaches in AISDs, explore the implications of their variable efficacy, and discuss future directions for development. We aim to provide broader perspectives for advancing targeted therapies in AISDs.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102643"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checkpoint agonists — immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis 检查点激动剂-免疫调节作用及其在银屑病和银屑病关节炎治疗中的意义
IF 5.8 2区 医学
Current Opinion in Immunology Pub Date : 2025-10-01 Epub Date: 2025-08-18 DOI: 10.1016/j.coi.2025.102641
Angel Ray Baroz , Debra K Lee , Natalia Maverakis Ramirez , Smriti K Raychaudhuri , Siba P Raychaudhuri
{"title":"Checkpoint agonists — immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis","authors":"Angel Ray Baroz ,&nbsp;Debra K Lee ,&nbsp;Natalia Maverakis Ramirez ,&nbsp;Smriti K Raychaudhuri ,&nbsp;Siba P Raychaudhuri","doi":"10.1016/j.coi.2025.102641","DOIUrl":"10.1016/j.coi.2025.102641","url":null,"abstract":"<div><div>Psoriasis and psoriatic arthritis are chronic autoimmune diseases characterized by dysregulated immune responses, particularly involving Th17 cells. Immune checkpoint molecules such as programmed death-1 (PD-1) and its ligands (PD-L1/PD-L2) are critical for maintaining immune tolerance. Disruptions in these pathways contribute to psoriatic disease pathogenesis. Notably, immune checkpoint inhibitors used in cancer therapy have been linked to the development of psoriasis or its exacerbation. This highlights the complex role of checkpoint pathways in psoriatic diseases. Thus, immune checkpoint agonists could be a therapeutic strategy aimed at restoring immune balance without widespread immunosuppression. Preclinical studies demonstrate that PD-1 agonists can mitigate inflammation by enhancing inhibitory signaling. Additionally, early-phase clinical trials in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis suggest potential benefits of PD-1 modulation in psoriasis. This review explores immune checkpoint agonists in psoriatic disease as a promising alternative to conventional immunosuppressants by selectively suppressing pathogenic T-cell activity.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102641"},"PeriodicalIF":5.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书